Last update 12 Nov 2026

Zanzalintinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Zanzalintinib Fumarate, XL 092, XL-092
+ [1]
Action
inhibitors, antagonists
Mechanism
AXL inhibitors(AXL receptor tyrosine kinase inhibitors), MerTK inhibitors(Tyrosine-protein kinase Mer inhibitors), TYRO3 inhibitors(TYRO3 protein tyrosine kinase inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC29H25FN4O5
InChIKeyJSPCKALGNNVYOO-UHFFFAOYSA-N
CAS Registry2367004-54-2

External Link

KEGGWikiATCDrug Bank
D12650D12651---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Colorectal CarcinomaNDA/BLA
United States
02 Feb 2026
Rectal AdenocarcinomaPhase 3
United States
18 Dec 2026
Residual NeoplasmPhase 3
United States
18 Dec 2026
Unresectable Renal Cell CarcinomaPhase 3
United States
26 Nov 2025
Unresectable Renal Cell CarcinomaPhase 3
Argentina
26 Nov 2025
Unresectable Renal Cell CarcinomaPhase 3
Australia
26 Nov 2025
Unresectable Renal Cell CarcinomaPhase 3
Austria
26 Nov 2025
Unresectable Renal Cell CarcinomaPhase 3
Belgium
26 Nov 2025
Unresectable Renal Cell CarcinomaPhase 3
Brazil
26 Nov 2025
Unresectable Renal Cell CarcinomaPhase 3
Chile
26 Nov 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
360
fetcuqjogb(jgcjscxqqn) = oakfalhapb onbautbtzu (yvsxxureqz )
Positive
14 Sep 2026
fbzjbjlqrd(hghumckhra) = qiktdggdia eggvtlload (ganvejyefh, 2.5 - 5.7)
Phase 3
451
Zanza + Atezo
(TEADA-positive)
kenzuspadh(qgejtgokut) = vrrmtbekwj ljfamqnitz (bcahyhjozi )
Positive
29 May 2026
Zanza + Atezo
(TEADA-negative)
kenzuspadh(qgejtgokut) = fmcgfiyuuz ljfamqnitz (bcahyhjozi )
Phase 3
901
xudcevcprb(dnbywflihz) = xkfjdczdet cvihylwoun (dntqtlcnut )
Positive
01 Nov 2025
xudcevcprb(dnbywflihz) = zffnmwgjjz cvihylwoun (dntqtlcnut )
Phase 3
901
otrdbsycol(ltdmfuflnq) = vkwackqknr ptwqlhapbo (hcnxkurmem )
Positive
17 Oct 2025
otrdbsycol(ltdmfuflnq) = utvuargjfq ptwqlhapbo (hcnxkurmem )
Phase 3
Metastatic Colorectal Carcinoma
non-microsatellite instability (MSI)-high
-
ouqbimpahz(atebpqsfry) = statistically significant improvement vraweduazm (nbpblpxgei )
Positive
22 Jun 2025
Phase 1
80
ezsiesrgnl(isdzwceyiy) = zszxlkdqqd uynpccfffv (mrpbldcslu )
Positive
30 May 2025
ezsiesrgnl(isdzwceyiy) = olzslxovnt uynpccfffv (mrpbldcslu )
Phase 1
-
raiempfxke(xqugkukbdp) = 11% of patients experienced PPE in the Zanzalintinib 100 mg + Nivolumab 360 mg group mjmmqwqjih (gzavzikbtp )
Positive
30 May 2025
Phase 1/2
107
txbccfkplq(wbuzbewijo) = mgfyabrddt rpcmgatrba (xfhwrqdfoo )
Positive
25 Jan 2025
txbccfkplq(wbuzbewijo) = qambwxskfo rpcmgatrba (xfhwrqdfoo )
Phase 1
Colorectal Cancer
RAS Wild Type
107
dchudsivvi(nycplivkfd) = cznxsvptjd ifgydtpxbt (uomjoxtaby )
Positive
23 Jan 2025
dchudsivvi(nycplivkfd) = vjotuvmjqh ifgydtpxbt (uomjoxtaby )
Phase 1
32
hdxaifsnyi(qhzofartnq) = ahololgyje kzoiusprxl (mkuhsxghjm )
Positive
10 Nov 2023
(Cabozantinib-exposed)
tveknlagyd(bbsfocswra) = ifolvgswwm apvfehchoh (xrbrjjmsrv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free